MX2023001865A - Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este. - Google Patents
Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este.Info
- Publication number
- MX2023001865A MX2023001865A MX2023001865A MX2023001865A MX2023001865A MX 2023001865 A MX2023001865 A MX 2023001865A MX 2023001865 A MX2023001865 A MX 2023001865A MX 2023001865 A MX2023001865 A MX 2023001865A MX 2023001865 A MX2023001865 A MX 2023001865A
- Authority
- MX
- Mexico
- Prior art keywords
- mutants
- dosage form
- formula
- btk inhibitor
- form compositions
- Prior art date
Links
- 229940124291 BTK inhibitor Drugs 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 2
- 150000001204 N-oxides Chemical class 0.000 abstract 2
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 abstract 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 abstract 1
- 239000001530 fumaric acid Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000155 isotopic effect Effects 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 239000007916 tablet composition Substances 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
En la presente descripción se proporcionan composiciones de comprimido farmacéuticas que comprenden un ácido orgánico (tal como ácido fumárico) y un compuesto de Fórmula (I), o un N-óxido de este, solvato, polimorfo, tautómero, estereoisómero, una forma isotópica o un profármaco de dicho compuesto de Fórmula (I) o N-óxido de este: (VER FORMULA) en donde el compuesto de Fórmula (I) es un inhibidor de la tirosina quinasa de Bruton.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063066105P | 2020-08-14 | 2020-08-14 | |
| PCT/US2020/047196 WO2021066958A1 (en) | 2019-10-05 | 2020-08-20 | Inhibitor of btk and mutants thereof |
| PCT/US2021/045867 WO2022036171A1 (en) | 2020-08-14 | 2021-08-13 | Dosage form compositions comprising an inhibitor of btk and mutants thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001865A true MX2023001865A (es) | 2023-05-09 |
Family
ID=80248192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001865A MX2023001865A (es) | 2020-08-14 | 2021-08-13 | Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230346779A1 (es) |
| EP (1) | EP4196124A1 (es) |
| JP (1) | JP2023537626A (es) |
| KR (1) | KR20230051200A (es) |
| CN (1) | CN116406259A (es) |
| AU (1) | AU2021326530A1 (es) |
| CA (1) | CA3189235A1 (es) |
| IL (1) | IL300428A (es) |
| MX (1) | MX2023001865A (es) |
| WO (1) | WO2022036171A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115960124B (zh) * | 2023-02-23 | 2025-02-18 | 康化（上海）新药研发有限公司 | 一种2-氟-3-甲酰基-吡啶-4-硼酸频哪醇酯的合成方法 |
| WO2025031344A1 (zh) * | 2023-08-07 | 2025-02-13 | 广州麓鹏制药有限公司 | 一种丙烯酰胺类化合物的晶型vi及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1934174T1 (sl) | 2005-10-07 | 2011-08-31 | Exelixis Inc | Inhibitorji MEK in postopki za njihovo uporabo |
| UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| AU2019222475B2 (en) | 2018-02-19 | 2024-08-15 | Guangzhou Lupeng Pharmaceutical Company Ltd. | Inhibitors of Btk and mutants thereof |
| JP2022522153A (ja) * | 2019-02-25 | 2022-04-14 | グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド | Ｂｔｋおよびその変異体の阻害剤 |
| WO2021066958A1 (en) * | 2019-10-05 | 2021-04-08 | Newave Pharmaceutical Inc. | Inhibitor of btk and mutants thereof |
-
2021
- 2021-08-13 CA CA3189235A patent/CA3189235A1/en active Pending
- 2021-08-13 JP JP2023511561A patent/JP2023537626A/ja active Pending
- 2021-08-13 WO PCT/US2021/045867 patent/WO2022036171A1/en not_active Ceased
- 2021-08-13 EP EP21765801.2A patent/EP4196124A1/en active Pending
- 2021-08-13 AU AU2021326530A patent/AU2021326530A1/en active Pending
- 2021-08-13 KR KR1020237006879A patent/KR20230051200A/ko not_active Withdrawn
- 2021-08-13 IL IL300428A patent/IL300428A/en unknown
- 2021-08-13 CN CN202180055258.XA patent/CN116406259A/zh active Pending
- 2021-08-13 MX MX2023001865A patent/MX2023001865A/es unknown
- 2021-08-13 US US18/020,980 patent/US20230346779A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3189235A1 (en) | 2022-02-17 |
| AU2021326530A9 (en) | 2025-04-10 |
| AU2021326530A1 (en) | 2023-04-20 |
| CN116406259A (zh) | 2023-07-07 |
| KR20230051200A (ko) | 2023-04-17 |
| US20230346779A1 (en) | 2023-11-02 |
| JP2023537626A (ja) | 2023-09-04 |
| WO2022036171A1 (en) | 2022-02-17 |
| EP4196124A1 (en) | 2023-06-21 |
| IL300428A (en) | 2023-04-01 |
| AU2021326530A8 (en) | 2023-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023013339A (es) | Inhibidor del factor b del complemento, y composicion farmaceutica del mismo, metodo de preparacion del mismo y uso del mismo. | |
| CR20220281A (es) | Derivados de pirazolilo útiles como agentes anti-cancerígenos | |
| SA519410865B1 (ar) | مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه | |
| AR121483A1 (es) | Hidrato cristalino de un compuesto inhibidor de jak | |
| CO2021010415A2 (es) | Inhibidor jak y método de preparación del mismo | |
| PH12018502227A1 (en) | Macrocyclic mcl1 inhibitors for treating cancer | |
| AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
| CU20160109A7 (es) | Compuestos de indazol como inhibidores de irak4 | |
| MX2021003739A (es) | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. | |
| AR063098A1 (es) | Pirazolopirimidinas como inhibidores de quinasas dependientes de ciclina | |
| GEAP202416075A (en) | New macrocyclic lrrk2 kinase inhibitors | |
| CO7131360A2 (es) | Novedosas n-piridinil amidas cíclicas sustituidas como inhibidores de quinasa | |
| MX2021013576A (es) | Compuesto utilizado como inhibidor de la quinasa y aplicación del mismo. | |
| MX2023001865A (es) | Composiciones de forma de dosificación que comprenden un inhibidor de btk y mutantes de este. | |
| MX389786B (es) | Derivados de 4-metil 7-{[5-heterociclilpirazina-2-il]amino}1,2- dihidro-1,6-naftiridina-5-ona como compuestos inhibidores de cdk4/6 y el uso de los mismos para el tratamiento de cáncer. | |
| EA202192900A1 (ru) | Модуляторы пути интегрированной реакции на стресс | |
| MX2021003662A (es) | Derivado de aminonorbornano y metodo de fabricacion del mismo y uso del mismo. | |
| CL2021002480A1 (es) | Agonistas compuestos macrocíclicos como de sting | |
| MX389378B (es) | Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos. | |
| CL2021002098A1 (es) | Inhibidor de la quinasa atr para usar en el tratamiento de una enfermedad hiperproliferativa. | |
| CO6331433A2 (es) | 2,6-diamino-pirimidin-5-ilcarboxamidas como inhibidores de syk p jak quinasas | |
| AR129185A1 (es) | Compuestos de 6-(pirimidin-4-il)quinolina sustituidos como inhibidores de la cinasa dependiente de ciclina | |
| WO2021133894A8 (en) | Btk inhibitors | |
| AR132764A1 (es) | Inhibidores de tyk2 y sus usos | |
| AR129212A1 (es) | Compuestos piridona como inhibidores de trpa1 |